MENU
+Compare
ARWR
Stock ticker: NASDAQ
AS OF
Dec 20, 04:59 PM (EDT)
Price
$19.45
Change
-$0.05 (-0.26%)
Capitalization
2.42B

ARWR Arrowhead Pharmaceuticals Forecast, Technical & Fundamental Analysis

a developer of novel drugs to treat intractable diseases

Industry Biotechnology
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for ARWR with price predictions
Dec 20, 2024

ARWR in downward trend: price dove below 50-day moving average on December 18, 2024

ARWR moved below its 50-day moving average on December 18, 2024 date and that indicates a change from an upward trend to a downward trend. In of 49 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ARWR moved out of overbought territory on December 04, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on December 12, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on ARWR as a result. In of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ARWR turned negative on December 12, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARWR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ARWR broke above its upper Bollinger Band on November 27, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for ARWR crossed bullishly above the 50-day moving average on November 29, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +3 3-day Advance, the price is estimated to grow further. Considering data from situations where ARWR advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 184 cases where ARWR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARWR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.055) is normal, around the industry mean (14.529). P/E Ratio (0.000) is within average values for comparable stocks, (87.563). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.739). ARWR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (666.667) is also within normal values, averaging (255.281).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARWR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ARWR is expected to report earnings to fall 71.13% to -39 cents per share on February 05

Arrowhead Pharmaceuticals ARWR Stock Earnings Reports
Q4'24
Est.
$-0.39
Q3'24
Missed
by $0.39
Q2'24
Missed
by $0.85
Q1'24
Missed
by $0.55
Q4'23
Missed
by $0.44
The last earnings report on November 26 showed earnings per share of -136 cents, missing the estimate of -97 cents. With 4.01M shares outstanding, the current market capitalization sits at 2.42B.
A.I. Advisor
published General Information

General Information

a developer of novel drugs to treat intractable diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
177 E. Colorado Boulevard
Phone
+1 626 304-3400
Employees
525
Web
https://www.arrowheadpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MCRFX14.180.16
+1.14%
BlackRock Mid-Cap Value Investor C
RUSTX16.580.18
+1.10%
Russell Inv US Strategic Equity M
VEIPX41.840.44
+1.06%
Vanguard Equity-Income Inv
SUPAX18.270.19
+1.05%
DWS Equity Sector Strategy Fund Class A
HSLTX48.300.43
+0.90%
Hartford Small Cap Growth R5

ARWR and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with NTLA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
-0.26%
NTLA - ARWR
49%
Loosely correlated
+0.83%
PGEN - ARWR
49%
Loosely correlated
+5.07%
BEAM - ARWR
47%
Loosely correlated
+8.04%
CRNX - ARWR
47%
Loosely correlated
+1.63%
ALNY - ARWR
46%
Loosely correlated
+2.75%
More